Extended dosing with CC‐486 (oral azacitidine) in patients with myeloid malignancies

CC‐486 (oral azacitidine) is an epigenetic modifier in clinical development for treatment of hematological cancers. This study of extended CC‐486 dosing included patients with myelodysplastic syndromes (MDSs), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML). After a pharmacok...

Descripción completa

Detalles Bibliográficos
Autores principales: Savona, Michael R., Kolibaba, Kathryn, Conkling, Paul, Kingsley, Edwin C., Becerra, Carlos, Morris, John C., Rifkin, Robert M., Laille, Eric, Kellerman, Amy, Ukrainskyj, Stacey M., Dong, Qian, Skikne, Barry S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221082/
https://www.ncbi.nlm.nih.gov/pubmed/30016552
http://dx.doi.org/10.1002/ajh.25216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221082/
https://www.ncbi.nlm.nih.gov/pubmed/30016552
http://dx.doi.org/10.1002/ajh.25216

Ejemplares similares